Thoughts and Progress

Similar documents
DEVELOPMENT OF FUNCTIONAL BIOENGINEERED MUSCLE MODELS AND A NOVEL MICRO-PERFUSION SYSTEM. Louise Hecker

Regenerative Medicine and Stem Cell Therapies

UNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE MEDICINE

Tissue Engineering of the Mitral Valve Leaflets and Abdominal Aorta

Whole Organ Bioengineering Science & Sensibility. Doris A. Taylor, PhD, FAHA, FACC Director, Regenerative Medicine Research Texas Heart Institute

Bioreactors in tissue engineering

Effect of Pulsatile Electric Field on Cultured Muscle Cells in Vitro

CHALLENGES OF 3D BIOPRINTING IN CLINICAL PRACTICE

Stem Cell Research From Bench to Bedside

ISTINYE UNIVERSITY FACULTY OF MEDICINE DEPARTMENT OF MEDICINE (ENGLISH) COURSE DESCRIPTIONS

Functional Assessment and Clinical Outcome

1) Determining the best cell sources and scaffold materials for TEHV development.

Regenerative medicine approaches to the treatment of cardiovascular disease

NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:

The Role of Adult Stem Cells in Personalized and Regenerative Medicine

Des cellules-souches dans le poumon : pourquoi faire?

Supplementary Information. Induction of functional tissue-engineered skeletal muscle. constructs by defined electrical stimulation

Bio-Plex. What s new?

The Healing Of Tibial And Calvarial Defect Using Runx2-transfected Adipose Stem Cells

White Paper: Designing Functional Fabrics for Today s Heart Valves and Beyond

Artificial blood vessels

ChE 125. Principles of Bioengineering

INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE

A UNIQUE POLYESTER DRUG/DEVICE VASCULAR GRAFT INTERGARD HEPARIN

Effect of Ultrasonic Vibration on Culture of Myoblast

Looking Ahead: The Bio-Artificial Kidney

Spying on Cells: Cellular and Subcellular Analysis using Novel Polymeric Micro- and Nanostructures. Xin Zhang Associate Professor.

Concept of Integrated Research Platforms

COATING SYSTEMS BIOLINE COATING

Regulation of advanced blood cell therapies

Promises and Challenges

Stem cells and tissue engineering

TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS

Recent advances in tissue-engineered corneal regeneration

ANAT 3231 Cell Biology Lecture 21 Stem Cells

Mechano-dependent biosynthetic response of microintegrated cells in elastomeric scaffolds.

10:10-10:22. YIA-1 A study of newly established human peripheral blood monocyte-derived ips cell line used in allergy research 10:22-10:32

In Vitro Angiogenesis Assay Kit

The Biomechanics of ProLayer Acellular Dermal Matrix: suture retention strength

Innovating to Create Value through New Perspectives and Synthesis

Nanosystems in regenerative medicine. Jöns Hilborn Materials Chemistry The Ångström Laboratory Uppsala University Sweden

Available through Online

Dr: RAWIA BADR Associate Professor of Microbiology&Immunology

Affinity. A Paradigm Shift in Skeletal Reconstruction

hpsc Growth Medium DXF Dr. Lorna Whyte

Translation of Biomaterial-based Therapies for the Treatment of Spinal Cord Injury: The Neuro-Spinal Scaffold and Bioengineered Neural Trails

Regenerative Strategies for Vascular and Lung Tissues. Laura E Niklason MD, PhD

Future implications of regenerative medicine on assisted reproductive technology. Regenerative medicine. History of Regenerative medicine

Course Code: BMEG5100 Course Title: Advanced Medical Robotics Course Code: BMEG5110 Course Title: Advanced Medical Devices and Sensor Networks

A NANOFIBROUS HYDROGEL FOR BONE TISSUE ENGINEERING

Defense Technical Information Center Compilation Part Notice

A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas

Rolling, Adhesion and Migration Assay Using SynRAM Idealized Network Kits and Chips Technical Manual Catalog #s , , SR

ACCEPTED MANUSCRIPT. In situ heart valve tissue engineering: Employing the innate immune response to do the

CHAPTER 1. Survey of Clinical Cases of Biomaterials-Tissue Interactions: The Paradigm

Stem cells in Development

Stem Cells, Regenerative Medicine and cgmp (GTP)

ISCT Telegraft Column: Mesenchymal Stromal Cell (MSC) Product Characterization and Potency Assay Development

Leading the world in novel adult stem cell therapies Half-Year Financial Results

Stem cells in Development

In Vitro Angiogenesis Assay Kit. Item No

ISTINYE UNIVERSITY INSTITUTE OF HEALTH SCIENCES DEPARTMENT OF STEM CELL AND TISSUE ENGINEERING (THESIS) COURSE DESCRIPTIONS

Stem cell: a cell capable of 1) tissue plasticity - make different cell types 2) infinite self renewal through asymmetric division

Tissue Engineering for Blood Vessels

New Opportunities Through Innovations Jacques Pirenne, Transplant Surgeon, Leuven

Realizing the Future that Regenerative Medicine Will Open

STEM CELLS BONE FRACTURE

Cardiomyocyte Differentiation Of Cord Lining Membrane Stem Cells. Phan T.H., Masilamani J. and Ng Y.H.

Stem Cells & Neurological Disorders. Said Ismail Faculty of Medicine University of Jordan

Some challenges in the development of new toxicity assays using in vitro methods

Stem Cells in Kidney Disease: Where Are We Now?

ANAT 2341 Embryology Lecture 18 Stem Cells

Advancing Manufacturing for Advanced Therapies

Promising Future for Ex vivo Tissue Fabrication. Eiji Kobayashi, MD, PhD Department of Organ Fabrication, Keio University School of Medicine, Japan

Cell and gene therapy: scaling up and moving to mass production

Revised Examination Guidelines for Industrially Applicable Inventions (Provisional Translation)

Background. Background. Background. Background. Background 3/4/2013

Seevix s SVXgro: A Spidersilk Scaffold for Tissue Engineering

University of Florida College of Engineering EDGE Course EMA 6590/6938: Advances in Biomaterials and Tissue Engineering for Healthcare

CAP-1002: HOPE Clinical Trials PPMD Annual Conference 2018

Development of an Automated, Uniaxial Tension System for Mechanically Active Tissue Culture

Chapter 8 Healthcare Biotechnology

This document is a preview generated by EVS

A Model-Free Adaptive Control to a Blood Pump Based on Heart Rate

About Clinical Trials: What They Can Mean For You?

Office of Patents and Licensing STEM CELLS & TISSUE ENGINEERING

Development of new polymeric biomaterials for in vitro and in vivo liver reconstruction

Special Issue. Mesoblast Limited

YOUR OWN LIFE

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach

The NYSCF Research Institute

Scaffolds Covalently Immobilized with VEGF and Angiopoietin-1 to Promote Angiogenesis In Engineered Cardiac Tissues

THE GLOBAL MARKET FOR STEM CELLS

Figure 1. Few examples of in-vitro models developed using our products

EMA s role & responsibility for the development of modern/advanced therapies

3/20/2017. R 3 Repair Paradigm REGENERATIVE MEDICINE GLOSSARY OF STEM CELL PLATFORMS. Limitations of Embryonic Stem Cells

Mechano-dependent Biosynthetic Response of Micro-integrated Cells in Elastomeric Scaffolds

Genetics Lecture 19 Stem Cells. Stem Cells 4/10/2012

GeneCellin TM HTC Transfection Reagent Protocol vs6 2/12

ALAMO HEIGHTS INDEPENDENT SCHOOL DISTRICT ALAMO HEIGHTS HIGH SCHOOL Anatomy and Physiology Curriculum Framework

Transcription:

aor_1007 69..91 Artificial Organs 35(1):69 91, Wiley Periodicals, Inc. 2010, Copyright the Authors Artificial Organs 2010, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc. Thoughts and Progress Fabrication of Functional Cardiac, Skeletal, and Smooth Muscle Pumps In Vitro Rebecca Evers, Luda Khait, and Ravi K. Birla Artificial Heart Laboratory, Division of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA Abstract: Cardiovascular disease is one of the leading causes of death in the United States, and new treatments need to be developed in order to provide novel therapies. Tissue engineering aims to develop biologic substitutes that restore tissue function. The purpose of the current study was to construct cell-based pumps, which can be viewed as biologic left ventricular assist devices. The pumps were fabricated by culturing cardiac, skeletal, and smooth muscle cells within a fibrin gel and then each 3-D tissue construct was wrapped around a decellularized rodent aorta. We described the methodology for pump fabrication along with functional performance metric, determined by the intra-luminal pressure. In addition, histologic evaluation showed a concentric organization of components, with the muscle cells positioned on the outermost surface, followed by the fibrin gel and the decellularized aorta formed the innermost layer. Though early in development, cell-based muscle pumps have tremendous potential to be used for basic and applied research, and with further development, can be used clinically as cell-based left ventricular assist devices. Key Words: Tissue engineering Regenerative medicine Heart Cell culture Pressure Decellular scaffold Tissue construct 3-D. Heart failure can be a result of many physiologic abnormalities, including myocyte death and dysfunction, ventricular remodeling postmyocardial infarction or any of these combinations (1). Current therapies to treat heart failure are limited to surgical transplantation, pharmaceutical intervention, and mechanic cardiac support (2). Even though these treatments have improved the quality of patient care, there are numerous limitations to these approaches. doi:10.1111/j.1525-1594.2010.01007.x Received August 2009; revised December 2009. Address correspondence and reprint requests to Dr. Ravi K. Birla, Section of Cardiac Surgery, University of Michigan, MSRB I, A510E, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA. E-mail: rbirla@umich.edu For example, mechanic circulatory support devices such as left ventricular assist devices (LVADs) are used as a bridge to cardiac transplantation; however, these devices suffer due to thrombogenicity, rejection, and infection (3). The ability to engineer a cellbased cardiac pump may provide an alternative to mechanic LVADs. A cell-based cardiac pump would be composed of a hollow chamber surrounded by contracting cardiac cells with one-way valves for unidirectional flow (4). The cell-based alternatives to mechanic LVADS would offer a higher degree of immune tolerance and would reduce the need for long-term anticoagulant and immunosuppression therapy. The goal of this study is to fabricate functional 3-D pumps from smooth, skeletal, and cardiac muscle cells, and to evaluate each pump s contractile capabilities in response to chemical and mechanic stimulation. MATERIALS AND METHODS Approval for animal use was granted by the University Committee for the Use and Care of Animals in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication 86-23, 1996). Aortas were excised from adult Sprague Dawley rats and were completely decellularized using a detergent-based process, according to a published protocol (5). Primary cardiac myocytes were isolated from 2- to 3-day old Sprague Dawley rat hearts using an established protocol (6). Skeletal muscle cells were isolated from rat soleus muscle using a previously published protocol (7). Vascular smooth muscle cells were purchased from Cambrex (Walkersville, MD, USA; catalog no. CC-2571, lot no. 4F1292) and cultured based on a previously published protocol (8). In order to fabricate 3-D pumps, tissue culture plates were prepared on the surface of a fibrin gel (Fig. 1A,B). Cardiac cells were plated at 1 10 6 cells/plate and skeletal/smooth muscle cells were plated at 0.5 10 6 cells/plate. The muscle cells were maintained under sterile cell culture conditions for a period of 4 5 days with media changes every other day. After the cell monolayer had compacted the fibrin gel to approximately 50% of the original volume, the decellularized aortas were placed at the 69

70 THOUGHTS AND PROGRESS FIG. 1. Methodology for pump formation. (A) Tissue culture surfaces were coated with polydimethylsiloxane and anchor points (size 0 braided silk sutures), pinned to the center of plate using 0.1-mm diameter mintuetin pins. (B) Primary cells (cardiac, skeletal, or smooth) were suspended in a fibrin gel and plated on the surface of the tissue culture plate. (C) Once gel compaction started (typically 3 4 days after initial cell plating), a decellularized aorta was pinned to the center of the plate. (D) Gel compaction continued, with the decellularized aorta positioned at the center of culture surface. (E) Attachment of the cell monolayer to the decellularized aorta resulted in the formation of a cell-based pump. (F) Photograph of a cell-based cardiac pump formed utilizing primary cardiac myocytes. (G J) Decellularization of rat aortas detergent-based process to remove cellular components was used. (G) Freshly isolated aorta. (H) Decellularized aorta. (I) Hematoxylin and eosin (H&E) stain of freshly isolated aorta cell nucleus identified by circle. (J) H&E stain of de-cellularized aortas no cells can be seen. center of the plates (Fig. 1C). The muscle cells continued to compact the fibrin gel toward the center of the culture surface (Fig. 1D). At the center of the plate, the cell monolayer was physically wrapped around the decellularized aortas using sterile forceps (Fig. 1E). The constructs were maintained for an additional 7 days to promote pump formation (Fig. 1F). Miniature pressure transducers were used to

THOUGHTS AND PROGRESS 71 measure intra-luminal pressure. For cardiac pumps, intra-luminal pressure was recorded in response to spontaneous contractions, in the absence of any electric or chemical stimulation. For skeletal muscle pumps, intra-luminal pressure was recorded in response to electric stimulation, using an impulse of pulse width of 1.2 ms, voltage of 20 V, and frequencies of 1 and 60 Hz. For smooth muscle pumps, the intraluminal pressure was recorded in response to chemical stimulation using 10 mm of norepinephrine (NE). All pressure measurements were conducted at a single time point of 14 days after initial cell plating. Following mechanical testing, the cell-based pumps were fixed and stained using hematoxylin and eosin (H&E). RESULTS Decellularization procedure We used a detergent-based decellularization protocol developed by our group. Using this protocol, we were able to completely remove cellular and nucleic material, while keeping the extracellular matrix intact. Macroscopic changes in the rodent aorta were observable as a loss of cellularity, which led to changes in tissue appearance (Fig. 1G,H). The efficiency of the decellularization protocol was assessed using H&E stain, and the absence of nucleic material was observed (Fig. 1I,J); an intact extracellular matrix can also be seen. This decellularization procedure was reproducibly repeated for 25+ rodent aortas. 3-D culture of cardiac, skeletal, and smooth muscle cells Previously described methods were used to culture primary cardiac, skeletal, and smooth muscle cells within a 3-D fibrin gel. Culture of primary cardiac cells within a fibrin gel resulted in a spontaneously contracting tissue construct, with macroscopic contractions observable under an inverted microscope at low magnification (10 ). Culture of primary skeletal muscle cells within a fibrin gel resulted in cell proliferation, seen using an inverted microscope, which demonstrated an increase in the surface area populated by skeletal myocytes. Changing the culture environment by reducing the media serum concentration promoted the formation of contracting myotubes; this led to fibrin gel compaction. Culture of primary smooth muscle cells (derived from an aortic source) resulted in cell proliferation and gel compaction; there were no macroscopic signs of spontaneous contractions and/or cell fusion. For each of the three cell types (cardiac, skeletal, and smooth), we fabricated 10+ plates by culturing within a 3-D fibrin gel and the behavior of the cells was consistent. 3-D pump formation In order to fabricate 3-D pumps, 8 mm segments of decellularized rat aortas were placed in the center of the compacting fibrin gel, with cardiac, skeletal, and/or smooth muscle cells (as described in Materials and Methods). Gel compaction resulted in radial movement of the fibrin gel toward the vessel segment. The fibrin gel was then physically wrapped around the decellularized vessel and subsequent culture resulted in 3-D pump formation. Over time, in culture, the cell monolayer became more compact and more closely associated with the aorta (evident under an inverted microscope). Spontaneous contractions (frequency of 1 2 Hz) of the 3-D pumps were observed only for the constructs fabricated using cardiac cells; these contractions were visible under an inverted microscope. A total of 30+ pumps were fabricated using this procedure with an 80% success rate, with success being defined as the formation of 3-D construct. In 10% of the pumps, there was contamination which likely resulted from the physical wrapping of the fibrin gel around decellularized vascular segments. In another 10% of the cases, the fibrin gel did not adhere to the vascular segments; rather, the 3-D fibrin gel with the muscle cells remained in culture as an independent entity. Functional evaluation of 3-D pumps intra-luminal pressure The intra-luminal pressure of 3-D cardiac pumps was measured during spontaneous contractions and was on average 0.12 mm Hg with the average frequency of 1.5 Hz (Fig. 2A). The smooth muscle pumps were only excitable upon chemical stimulation and in response to 10 mm NE, an average pressure of 0.008 mm Hg was obtained (Fig. 2B). For the skeletal pump, there were no spontaneous contractions and intra-luminal pressure was only recorded upon electric stimulation (Fig. 2C,D). When the 3-D skeletal pumps were electrically stimulated at a frequency of 1 Hz, the number of pressure waves correlated with the pacing frequency; individual twitch contractions were observed (Fig. 2C). However, when the pacing frequency was increased to 60 Hz, tetanus contractions were observed, with a magnitude of 0.025 mm Hg (Fig. 2D). Histologic evaluation of 3-D pumps Histologic evaluation of the pumps showed the presence of an intact acellular vessel, with concentric

72 THOUGHTS AND PROGRESS FIG. 2. Functional performance of cell-based pumps. (A) Cardiac pump in the absence of electric stimulation, the cardiac pumps were capable of generating spontaneous contractions. The average pressure was on the order of 0.014 mm Hg and the frequency of spontaneous contractions was approximately 1.5 Hz. (B) Smooth muscle pump the smooth muscle pumps were stimulated with 10 mm of norepinephrine (NE) and the intra-luminal pressure recorded for a period of 140 s. The point at which the NE was added is indicated by an arrow. The average pressure was recorded to be 0.008 mm Hg. (C D) Skeletal muscle pump the skeletal muscle pumps were subjected to electric stimulation, using a pulse width of 1.2 ms, voltage of 20 V, and two different frequencies: (C) 1 Hz and (D) 60 Hz. The average pressure was 0.025 mm Hg at 60 Hz. (E) Histologic evaluation of muscle-based pump a segment of decellularized aortic tissue was used as the scaffold material, with primary muscle cells culture in a fibrin gel, wrapped around the peripheral surface. (F) Tri-layer structure of 3-D pump a high magnification image of the muscle-based pump showing the organization of the decellular aorta, fibrin gel, and muscle cells. Images are for skeletal muscle pump and are representative of pumps fabricated with all three muscle types (cardiac, skeletal, and smooth).

THOUGHTS AND PROGRESS 73 alignment of a fibrin gel followed by muscle cells on the outer surface of the 3-D pump (Fig. 2E). The acellular vessel was completely intact and retained its 3-D architecture, and it was evident that no cellular material was present within the vascular segment (Fig. 2F). The cell component of the pump was separated from the vascular segment by the fibrin gel; this prevented physical contact between the cells and the vascular segment (Fig. 2F). However, cells were evident around the entire circumferential surface of the 3-D pumps. This arrangement of the vascular segment, fibrin gel, and muscle cells was independent of the cell type being used and was a function of the methodology implemented for the formation of 3-D pumps. DISCUSSION AND CONCLUSIONS In this study, we describe a novel method to bioengineer 3-D cell-based pumps using cardiac, skeletal, and smooth muscle cells. We describe the methodology for pump formation and demonstrate functional performance based on intra-luminal pressure. In this section, we discuss the following five topics: (i) the need for cell-based pumps; (ii) methodology for pump formation; (iii) functional performance of cell-based pumps; (iv) technological advancements required to develop these pumps further; and (v) path to clinical applications. Need for cell-based pumps In this study, we describe methodology to fabricate functional 3-D cell-based pumps. The concept of cellbased pumps has not been extensively explored in the research literature and very few scientific publications can be found discussing this topic. Therefore, prior to presenting our discussion for this study, it would be useful to describe what exactly cell-based pumps are and how can they be used in a research and/or clinical setting. Cell-based pumps can be viewed as biologic devices capable of generating pressure upon spontaneous or electrically/chemically induced contractions. Although these devices are early in development, they can be conceptually viewed as biologic alternatives to LVADs. LVADs are used as a bridge to heart transplantation and function by pumping blood directly from the apex of the heart to the aorta, completely bypassing the failing left ventricle. However, LVADs are devices and suffer from thrombogenicity problems, something cellbased alternatives would reduce. Methodology for 3-D pump formation In order to fabricate 3-D pumps, primary muscle cells were cultured within a 3-D fibrin gel and then physically wrapped around a decellularized aortic vascular segment. This resulted in the fibrin gel being placed in close proximity to the decellular scaffold, leading to attachment of the fibrin gel to the scaffold and the formation of 3-D cell-based pumps. This method is simple, easy to implement and reproducible, and most importantly, leads to the formation of functional pumps. However, one limitation is the distance between the muscle cells and acellular matrix, with fibrin gel occupying a substantial volume in between these two layers. This distance between the muscle cells and acellular scaffolds dampens the contractile activity of the cells, thereby reducing scaffold displacement; this reduces pump functionality, measured by intra-luminal pressure. This is the most likely explanation of low pressures obtained in this study. While adequate for a proof of concept study, subsequent work will need to focus on functional integration between the muscle cells and the scaffold. This can be accomplished by promoting fibrin degradation or replacing the 3-D culture system from a fibrin-based model to one based on self organization strategies. Functional performance of cell-based pumps The functional performance of the 3-D pumps, fabricated using any of the three muscle cell types, was considerably lower than that of mammalian tissue. This could partly be due to the concentric organization of the acellular scaffold, fibrin gel, and muscle cells, with the fibrin gel presenting a barrier between the cells and the scaffold. Another possible explanation for the low functional performance of the pumps is the single layer of cells which was used in this study. An increase in intra-luminal pressure of the 3-D pumps will require multi-layering of the muscle cells coupled with functional integration of the cells with the scaffold, without physical hindrance of the intervening fibrin gel. While these strategies would be required for further development of the pump model, the current study does provide the foundation and serves as a proof of concept study. Technological advancements required to develop these pumps further In order to develop the pump model further, the functional performance of these devices will need to be closer to that of mammalian tissue. This can be accomplished by increasing the thickness of the muscle layer and promoting functional integration between the cells and the scaffold. While the exact number of cell layers required remains unknown, multiple layers will be required; vascularization may also be needed to support the metabolic activity of

74 THOUGHTS AND PROGRESS the increase in cell number. In addition, physiologic conditioning using mechanical stretch, pulsatile fluid flow, and chemical conditioning with growth factors will be required. It will also be important to control the electric activity of the muscle cells and externally control stimulation variables (frequency, introduction of rest periods for skeletal muscle) during longterm in vitro culture; bioreactors with embedded stimulators will be required. Path to clinical applications The muscle-based pumps are at a nascent stage of development, and considerable research needs to be invested prior to using these devices clinically. Perhaps the most important step in moving the pump model forward will be the use of stem cells in place of the primary cells used in this study. Several stem cell sources are currently under investigation and human embryonic stem cells, mesenchymal stem cells, and induced pluripotent cells are all potential sources for tissue engineering. From an applications standpoint, cardiac pumps can be used as actuators in robotic devices, where continuous performance is necessary. Skeletal and smooth muscle pumps will be suitable as miniature drug delivery devices, with skeletal pumps being suitable for infrequent delivery of high drug doses and smooth pumps being better for frequent delivery of low doses of specific molecule. Acknowledgment: The authors would like to thank the Section of Cardiac Surgery at the University of Michigan for financial support. REFERENCES 1. Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999;44:232 41. 2. Hecker L, Birla R. Engineering the heart piece by piece: state of the art in cardiac tissue engineering. Regen Med 2007;2:125 44. 3. Stevenson LW, Kormos RL. Mechanical cardiac support 2000: current applications and future trial design. J Heart Lung Transplant 2001;20:1 38. 4. Khait L, Birla RK. Cell-based cardiac pumps and tissueengineered ventricles. Regen Med 2007;2:391 406. 5. Borschel GH, Kia KF, Kuzon WM Jr, Dennis RG. Mechanical properties of acellular peripheral nerve. J Surg Res 2003;114: 133 9. 6. Huang YC, Khait L, Birla RK. Contractile three-dimensional bioengineered heart muscle for myocardial regeneration. J Biomed Mater Res A 2007;80:719 31. 7. Dennis RG, Kosnik PE. Excitability and isometric contractile properties of mammalian skeletal muscle constructs engineered in vitro. In Vitro Cell Dev Biol Anim 2000;36:327 35. 8. Hecker L, Khait L, Welsh MJ, Birla RK. Bioengineering functional human aortic vascular smooth muscle strips in vitro. Biotechnol Appl Biochem aor_1018 74..96 2008;50:155 63.